From the CEO's Desk
Swaroop Vakkalanka, PhD
Founder & CEO
Rhizen’s tryst with drug discovery and development created a rich pipeline of differentiated products. There is a constant need for innovative therapies that could influence human lives positively.
Rhizen Pharma was founded with a vision to discover and develop novel onco-therapeutics designed to improve the quality of life of patients and drive transformative outcomes.
Rhizen is deeply committed to fulfilling this vision to address the immense unmet need that exists for patients living with cancer.
Rhizen Pharma was founded with a vision to discover and develop novel onco-therapeutics designed to improve the quality of life of patients and drive transformative outcomes.
Rhizen is deeply committed to fulfilling this vision to address the immense unmet need that exists for patients living with cancer.
At Rhizen we practice
Fostering a culture of cutting-edge innovation as has been evidenced by our pivotal leadership in the “Targeted Drugs for Oncology & Inflammation” space through our focus on platforms that are fortified with foundational and expansive assets
Staying focused on the patient care with a relentless drive; tracking the evolution of relevant biology and explore remedies for challenges thrown
Creative collaboration and partnerships across global markets and research institutes
Purposeful communication to ensure the team’s focus on imaginative outcomes As we head into 2025 with aspirations to grow as full-fledged development company,
We firmly believe we are poised to make tangible difference to cancer care and to potentially bring to market innovative medicines fostering productive collaborations. This is at the core of our philosophy and shapes the values at our company.
Latest News
To read more about Rhizen in the News, click here
Recent Publications
Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome
Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common subtypes of cutaneous T cell lymphomas (CTCL). Advanced-stage MF/SS have poor prognoses and may be refractory to multiple systemic treatments. These cases can be difficult to achieve and maintain complete response and there is a need for novel therapeutics. Inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway by Tenalisib presents one such emerging drug. We report a relapsed/refractory SS patient achieving complete remission using the combination of Tenalisib and Romidepsin and subsequently maintaining long-duration CR with Tenalisib monotherapy.
P35 – Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Initial results from a phase II study (ASCO 2022) Hyperactivation of the PI3K pathway in breast cancer is implicated in malignant transformation, cancer progression, and resistance to endocrine therapy. Salt Inducible Kinase- 3 (SIK3) is highly expressed in breast cancer and elevated SIK3 expressions are shown to contribute to tumorigenesis. Tenalisib (RP6530), a highly selective PI3K δ/γ and SIK3 inhibitor has been evaluated in > 150 patients with haematological malignancies and demonstrated encouraging activity in T-cell lymphoma with a differentiated safety profile. Tenalisib has a major metabolite (IN0385) which shows potent SIK3 inhibition. Preclinical studies in breast cancer cell lines have demonstrated that Tenalisib potentiated the activity of taxol and doxorubicin. The aim of this phase II study was to investigate the efficacy and safety of single-agent tenalisib in patients (pts) with HR+ HER2- locally advanced or metastatic breast cancer (MBC)
183P – Efficacy and Safety of Tenalisib, a PI3K δ/γ and SIK3 inhibitor in Patients with Locally Advanced or Metastatic Breast Cancer: Initial results from a Phase II study (ESMO 2022) Hyperactivation of PI3K pathway in breast cancer is implicated in malignant transformation, progression, and resistance to endocrine therapy. Salt Inducible Kinase- 3 (SIK3) is highly expressed in breast cancer and elevated SIK3 is shown to contribute to tumorigenesis. Tenalisib (RP6530), a PI3K δ/γ and SIK3 inhibitor has been evaluated in patients with haematological malignancies and demonstrated encouraging activity in T-cell lymphoma. Tenalisib’s major metabolite (IN0385) shows potent SIK3 inhibition Preclinical studies in breast cancer cell lines have demonstrated that tenalisib potentiates activity of taxol and doxorubicin
1233: Preclinical profile of RP12146, a novel, selective, and potent small molecule inhibitor of PARP1/2 in solid tumors (AACR 2022) RP12146 is a next generation potent, small molecule selective PARP 1/2 inhibitor with a wide therapeutic window with no evidence of dose limiting toxicities reported for the first-generation inhibitors.
5492 – Activity of RP7214, a novel, selective, and potent small molecule inhibitor of DHODH, in AML (AACR 2022) RP7214 is a novel and potent DHODH inhibitor that inhibited DHODH activity in enzyme and PHA induced HWB/PBMC proliferation with IC50 and EC50 values of 7.8 & 2.5/0.60 nM respectively. Herein, we describe the efficacy of RP7214 as a single agent and in combination with standard of care drugs in preclinical models of AML
P35 – Efficacy and safety of tenalisib, a PI3K δ/γ and SIK3 inhibitor in patients with locally advanced or metastatic breast cancer: Initial results from a phase II study (ASCO 2022) Hyperactivation of the PI3K pathway in breast cancer is implicated in malignant transformation, cancer progression, and resistance to endocrine therapy. Salt Inducible Kinase- 3 (SIK3) is highly expressed in breast cancer and elevated SIK3 expressions are shown to contribute to tumorigenesis. Tenalisib (RP6530), a highly selective PI3K δ/γ and SIK3 inhibitor has been evaluated in > 150 patients with haematological malignancies and demonstrated encouraging activity in T-cell lymphoma with a differentiated safety profile. Tenalisib has a major metabolite (IN0385) which shows potent SIK3 inhibition. Preclinical studies in breast cancer cell lines have demonstrated that Tenalisib potentiated the activity of taxol and doxorubicin. The aim of this phase II study was to investigate the efficacy and safety of single-agent tenalisib in patients (pts) with HR+ HER2- locally advanced or metastatic breast cancer (MBC)
183P – Efficacy and Safety of Tenalisib, a PI3K δ/γ and SIK3 inhibitor in Patients with Locally Advanced or Metastatic Breast Cancer: Initial results from a Phase II study (ESMO 2022) Hyperactivation of PI3K pathway in breast cancer is implicated in malignant transformation, progression, and resistance to endocrine therapy. Salt Inducible Kinase- 3 (SIK3) is highly expressed in breast cancer and elevated SIK3 is shown to contribute to tumorigenesis. Tenalisib (RP6530), a PI3K δ/γ and SIK3 inhibitor has been evaluated in patients with haematological malignancies and demonstrated encouraging activity in T-cell lymphoma. Tenalisib’s major metabolite (IN0385) shows potent SIK3 inhibition Preclinical studies in breast cancer cell lines have demonstrated that tenalisib potentiates activity of taxol and doxorubicin
1233: Preclinical profile of RP12146, a novel, selective, and potent small molecule inhibitor of PARP1/2 in solid tumors (AACR 2022) RP12146 is a next generation potent, small molecule selective PARP 1/2 inhibitor with a wide therapeutic window with no evidence of dose limiting toxicities reported for the first-generation inhibitors.
5492 – Activity of RP7214, a novel, selective, and potent small molecule inhibitor of DHODH, in AML (AACR 2022) RP7214 is a novel and potent DHODH inhibitor that inhibited DHODH activity in enzyme and PHA induced HWB/PBMC proliferation with IC50 and EC50 values of 7.8 & 2.5/0.60 nM respectively. Herein, we describe the efficacy of RP7214 as a single agent and in combination with standard of care drugs in preclinical models of AML
The Rhizen Blog
Coming Soon!
